Madhavi Thomas, MD
Neurology · Flower Mound, TXNPI 1558337238
Payments from drug & device makers
Across 336 payments — averaging $370.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kyowa Kirin, Inc.$102K
- Adamas Pharmaceuticals, Inc.$8K
- Acorda Therapeutics, Inc$5K
- Medtronic$4K
- AbbVie$3K
- Abbott$465
- plus $2K from 22 others
Across 2 payments — averaging $1000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acadia Pharmaceuticals Inc$2K
What the payments were for
- Consulting fees$21,02317%
- Speaking & faculty fees$89,43272%
- Travel & lodging$7,5896%
- Food & beverage$6,4315%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kyowa Kirin, Inc. | 66 | $102,041 |
| Adamas Pharmaceuticals, Inc. | 12 | $8,302 |
| Acorda Therapeutics, Inc | 22 | $4,906 |
| Medtronic(2 entities) | 68 | $3,556 |
| AbbVie(2 entities) | 17 | $2,797 |
| Abbott | 17 | $465 |
| Boston Scientific | 17 | $438 |
| Sunovion Pharmaceuticals Inc. | 20 | $351 |
| Acadia Pharmaceuticals Inc | 26 | $341 |
| Teva Pharmaceuticals USA, Inc. | 17 | $277 |
| MDD US Operations, LLC | 14 | $248 |
| UCB, Inc. | 7 | $145 |
| Lundbeck LLC | 7 | $133 |
| Amneal Pharmaceuticals LLC | 5 | $122 |
| Neurocrine Biosciences, Inc. | 4 | $79 |
| Vertical Pharmaceuticals, LLC | 4 | $56 |
| Amgen(2 entities) | 2 | $44 |
| Merz Pharmaceuticals, LLC | 1 | $21 |
| Aquestive Therapeutics, Inc. | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Biogen | 1 | $20 |
| Avion Pharmaceuticals | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Upsher-smith Laboratories LLC | 1 | $15 |
| GE HealthCare | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Aprecia Pharmaceuticals, LLC | 1 | $12 |
| Eisai Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$124,484 in reported general payments places this provider in the 85th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 82 | $518,513 |
| RytaryCarbidopa/Levodopa | 268 | $347,045 |
| IngrezzaValbenazine Tosylate | 27 | $265,332 |
| AustedoDeutetrabenazine | 18 | $197,546 |
| NeuproRotigotine | 90 | $127,496 |
| NourianzIstradefylline | 24 | $69,819 |
| InbrijaLevodopa | 11 | $48,720 |
| BotoxOnabotulinumtoxina | 46 | $46,084 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $21,983 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 622 | $18,866 |
| Tetrabenazine | 11 | $18,536 |
| AmantadineAmantadine Hcl | 169 | $7,462 |
| Rasagiline Mesylate | 34 | $6,038 |
| RivastigmineRivastigmine Tartrate | 70 | $4,077 |
| ValiumDiazepam | 12 | $3,918 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $341 | $518,51382 claims |
| Amneal Pharmaceuticals LLCRytary | $122 | $347,045268 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $79 | $265,33227 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $277 | $197,54618 claims |
| UCB, Inc.Neupro | $145 | $127,49690 claims |
| Kyowa Kirin, Inc.Nourianz | $102,041 | $69,81924 claims |
| Acorda Therapeutics, IncInbrija | $4,906 | $48,72011 claims |
| AbbVieBotox | $2,797 | $46,08446 claims |
| Upsher-smith Laboratories LLCTopiramate | $15 | $43637 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,246 neurology providers in Texas.
Other neurology in Flower Mound
- Ann BassSan Antonio$12.3M
- Kandasami SenthilkumarBeaumont$7.6M
- Bharathy SundaramSherman$7.2M
- Bhupesh DiheniaLubbock$6.9M
- Jamshid LotfiHouston$6M
- Nazanin MajdHouston$5.9M
- Aziz ShaibaniHouston$5.5M
- Elizabeth PeckhamRound Rock$5.4M
- Susan IannacconeDallas$5.1M
- Benjamin GreenbergDallas$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.